SCHEMBL4133787

SCHEMBL4133787

Clc1cc(Nc2ccc3c(c2)OCO3)cc(Cl)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
PTGS2 P35354 3/20 0.51
ALOX5 P09917 1/20 0.51
CLK1 P49759 2/20 0.49
DYRK1A Q13627 2/20 0.49
CLK4 Q9HAZ1 2/20 0.49
DYRK1B Q9Y463 2/20 0.49
CLK2 P49760 1/20 0.49
NPC1 O15118 5/20 0.48
RAB9A P51151 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
GAA P10253 1/20 0.47
POLB P06746 1/20 0.47
HSD17B10 Q99714 2/20 0.46
TSHR P16473 1/20 0.46
ADRA2A P08913 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378949 0.84 SMN1; SMN2 (0.62) LMNACLK1DYRK1ACLK4DYRK1B
SCHEMBL1920755 0.82 NPC1 (0.60) LMNACLK1DYRK1ACLK4DYRK1B
SCHEMBL18177441 0.79 POLA1 (0.61) LMNAPTGS2ALOX5CLK1DYRK1A
SCHEMBL13326012 0.79 LMNA (0.62) LMNAPTGS2ALOX5CLK1DYRK1A
SCHEMBL1921386 0.77 CLK1 (0.55) LMNAPTGS2ALOX5CLK1DYRK1A
SCHEMBL11559669 0.76 ULK1 (0.51) LMNAPTGS2ALOX5CLK1DYRK1A
SCHEMBL11469590 0.76 ALDH1A1 (0.62) LMNACLK1DYRK1ACLK4DYRK1B
SCHEMBL657553 0.75 BRAF (0.53) LMNAALOX5NPC1RAB9ASMN1; SMN2
SCHEMBL7926077 0.75 EGFR (0.58) LMNAPTGS2CLK4NPC1RAB9A
SCHEMBL6945105 0.75 LMNA (0.62) LMNAPTGS2ALOX5CLK1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1805142-A4 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS INC (US) 2009-06-10 EP claimed
EP-1805142-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-07-11 EP claimed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US claimed
WO-2006034474-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO claimed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them LDLR, LRP6, PLPBP LMNA 466/4885PTGS2 604/4885ALOX5 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.